Detection of circulating tumor-DNA as a 'liquid biopsy' in patients with Ewing Sarcoma and PNET: a pilot study

Detection of circulating tumor-DNA as a 'liquid biopsy' in patients with Ewing Sarcoma and PNET: a pilot study - /

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009029

Enrollment

Registered

2015-11-03

Start date

2015-06-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ewing-Sarcoma (C41.9) primitive neuroectodermal tumor (C71.9) C41.9 C71.9

Interventions

Group 1: Analysis of miRNA-profiles/detection of the EWS-FLI1- fusion gene in the peripheral blood of patients with Ewing Sarcoma /Primitive Neuroectodermal Tumors Group 2: Analysis of miRNA-profiles

Eligibility

Sex/Gender

All

Age

1 Years to 100 Years

Inclusion criteria

Inclusion criteria: Ewing-Sarcoma /PNET

Exclusion criteria

Exclusion criteria: other malign tumors, systemic diseases

Design outcomes

Primary

Measure	Time frame
Detection of tumorspecific DNA in the peripheral blood of patients with Ewing-Sarcoma/ PNET	—

Secondary

Measure	Time frame
Detection of a tumorspecific miRNA signature in the peripheral blood of patients with Ewing-Sarcoma/ PNET	—

Countries

Germany

Contacts

Public ContactAlba Fricke

UNIVERSITÄTSKLINIKUM FREIBURG Klinik für Plastische und Handchirurgie

alba.fricke@uniklinik-freiburg.de+49 761 270-24010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026